Lamisilonce (Terbinafine)

Terbinafine inhibits the fungal enzyme squalene epoxidase, which is essential for ergosterol synthesis. Blocking this step leads to toxic accumulation of squalene and depletion of ergosterol, disrupting the fungal cell membrane and causing fungal cell death.

The specific amount and frequency of Lamisilonce are determined by the prescribing healthcare professional based on the infection type, severity, and patient characteristics. Patients should follow the prescriber’s instructions and not alter the regimen on their own.

Safety data for topical terbinafine during pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient before prescribing.

To request Lamisilonce, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azole antifungals, terbinafine has a different target (squalene epoxidase) and often achieves faster clinical cure rates for dermatophyte infections. It is generally well‑tolerated topically, but choice of therapy should consider infection type, patient history and local resistance patterns.

Lamisilonce should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Apply a thin layer of the cream to the affected skin area once or twice daily, as directed by the prescriber. Wash hands before and after application, and avoid covering the treated area with airtight dressings unless instructed.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, extensive skin rashes like Stevens‑Johnson syndrome or toxic epidermal necrolysis, and signs of liver dysfunction. Patients should seek immediate medical attention if they notice swelling, difficulty breathing, widespread rash, or jaundice.

Individuals with known hypersensitivity to terbinafine or any component of the formulation should avoid using Lamisilonce. It is also contraindicated on broken skin, mucous membranes, or in patients who have experienced severe systemic reactions to topical antifungals.